Detalles de la búsqueda
1.
Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
Adv Ther
; 41(6): 2282-2298, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38619721
2.
Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe.
Curr Med Res Opin
; 39(9): 1205-1214, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37545338
3.
Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study.
Curr Med Res Opin
; 39(12): 1695-1705, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37927078
4.
Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.
BMC Neurol
; 12: 2, 2012 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-22316501
5.
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.
BMJ Open
; 10(8): e032552, 2020 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32792421
6.
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK.
Pharmacoecon Open
; 4(4): 635-648, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32166657
7.
Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
RMD Open
; 6(1)2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32094304
8.
Public health policy decisions on medical innovations: what role can early economic evaluation play?
Health Policy
; 89(2): 184-92, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18619704
9.
Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine.
BMC Health Serv Res
; 8: 194, 2008 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-18816378
10.
Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain.
Clinicoecon Outcomes Res
; 10: 747-759, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30519064
11.
Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
J Med Econ
; 21(8): 810-820, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29873270
12.
EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
J Med Econ
; 20(1): 19-27, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27471948
13.
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
J Med Econ
; 20(12): 1224-1230, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28760056
14.
Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.
Int J Technol Assess Health Care
; 24(4): 465-72, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18828942
Resultados
1 -
14
de 14
1
Próxima >
>>